Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebeglogene Autotemcel for Transfusion-Dependent Beta-Thalassemia
NCT06308159Phase 2Active, not recruiting
- Sponsor
- Lantu Biopharma
- Start
- May 2024
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of vebeglogene autotemcel in beta thalassemia, sponsored by Lantu Biopharma. Started May 2024; status: active, not recruiting.
02
Drugs
vebeglogene autotemcel
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06308159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308159.